Tsiogka Aikaterini, Gregoriou Stamatios, Stratigos Alexander, Soulaidopoulos Stergios, Rompoti Natalia, Panagakis Pantelis, Papoutsaki Marina, Kostakis Panagiotis, Kontochristopoulos George, Tsioufis Konstantinos, Campanati Anna, Offidani Annamaria, Vlachopoulos Charalambos, Rigopoulos Dimitrios
First Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 16121 Athens, Greece.
First Cardiology Department, Hippokration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Biomedicines. 2023 Jan 23;11(2):318. doi: 10.3390/biomedicines11020318.
Accumulating evidence considers psoriasis a systemic inflammatory disorder that is associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Although the precise pathogenetic links between psoriasis and atherosclerosis warrants further investigation, it is believed that chronic systemic inflammation along with the T helper (Th)-1 and Th17 polarization are associated with endothelial dysfunction and subsequent acceleration of atherosclerosis. Considering the above, several studies have evaluated if optimal control of the inflammation in psoriasis by inhibiting interleukins targeting the Interleukin (IL)-23/Th17 axis could subsequently reduce the atherosclerotic process during anti-psoriatic treatment by using a variety of surrogate markers of subclinical atherosclerosis. This systematic review summarizes current knowledge on the pathogenetic mechanisms and diagnostic evaluation of atherosclerosis in the context of psoriasis and provides a systematic review of the literature on the impact of treatment with biologics targeting the IL-23/Th17 axis on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis.
越来越多的证据表明，银屑病是一种全身性炎症性疾病，与银屑病关节炎、心血管疾病和代谢综合征等合并症相关。尽管银屑病与动脉粥样硬化之间的确切发病机制联系尚需进一步研究，但据信慢性全身性炎症以及辅助性T细胞（Th）-1和Th17极化与内皮功能障碍及随后动脉粥样硬化的加速有关。考虑到上述情况，多项研究评估了通过抑制靶向白细胞介素（IL）-23/Th17轴的白细胞介素，对银屑病炎症进行最佳控制是否随后可通过使用各种亚临床动脉粥样硬化替代标志物，在抗银屑病治疗期间减少动脉粥样硬化进程。本系统评价总结了银屑病背景下动脉粥样硬化发病机制和诊断评估的当前知识，并对靶向IL-23/Th17轴的生物制剂治疗对斑块状银屑病和/或银屑病关节炎患者亚临床动脉粥样硬化影响的文献进行了系统评价。
